<DOC>
	<DOCNO>NCT00574743</DOCNO>
	<brief_summary>This study evaluate safety efficacy EC-MPS ( ERL080 ) comparison MMF de novo heart recipient .</brief_summary>
	<brief_title>Efficacy Safety Enteric-coated Mycophenolate Sodium ( EC-MPS ) Comparison Mycophenolate Mofetil ( MMF ) de Nove Heart Patients</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion Male female cardiac patient 1865 year old undergoing primary heart transplantation treat CSME corticosteroid basic immunosuppression . Females childbearing potential must negative serum pregnancy test within 7 day prior enrollment . Effective contraception must use trial 6 week follow discontinuation study medication , even history infertility . Patients willing able participate full course study write informed consent obtain . Exclusion criteria Patients donor heart great 60 year age and/or cold ischemia time 6 hour and/or donor heart obvious coronary disease know heart disease time transplant . Patients Left Ventricular Assist Device receive immunotherapy prior transplantation schedule receive immunotherapy thereafter . Patients Panel Reactive Antibodies ( PRA ) 25 % . Patients serum creatinine 3.0mg/dL.. Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception . Patients history significant coagulopathy medical condition require long term anticoagulation transplantation ( low aspirin treatment allow ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>ERL080A , Heart Transplantation , Mycophenolate , EC-MPS</keyword>
</DOC>